

\$1.2 MILLION NIGMS GRANT TO FUND CURZA'S FIGHT AGAINST ANTIMICROBIAL RESISTANCE

Titled "Synthetic and biological investigations of 2-aminoimidazole derived natural products"

SALT LAKE CITY, Utah—September, 2016—The National Institute of General Medical Studies awarded a \$1.2 million grant to Curza and the University of Utah, titled "Synthetic and biological investigations of 2-aminoimidazole derived natural products."

The aim of the research is to further test the lead compounds of Curza's small-molecule therapeutics, which have been found to effectively treat breast cancer during in-vivo testing.

Besides skin cancer, breast cancer is the most commonly diagnosed cause of cancer in women; one in eight women will develop breast cancer in their lifetime, and 40,610 American women are expected to die of breast cancer in 2017. This naturally inspired small-molecule oncology drug could offer respite for the millions of people whose lives are affected by breast cancer.

About the National Institute of General Medical Studies—Established in 1962, NIGMS provides grants that primarily fund the research of scientists at universities, medical schools, hospitals and research institutions. The vast majority of this money funds grants to scientists at universities, medical schools, hospitals and research institutions throughout the country. At any given time, NIGMS supports more than 3,000 investigators and 4,500 research grants with a budget of \$2.5 billion.

About Curza— Curza is a Utah-based drug development company focused on developing novel therapeutics to combat antibiotic resistant bacteria. With original technology licensed from the University of Utah, Curza is in the early stages of developing two novel classes of antibiotics. Headquartered in Salt Lake City, UT with offices in Cambridge, MA, Curza is privately held and is backed by Clarke Capital Partners and other private investors. Visit www.curza.com for more information.

For press inquires contact Ryan Davies: rd@curza.com